exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088218 RNA Name: hsa-miR-362-3p RNA Type: miRNA Chromosome: chrX Starnd: + Coordinate: Start Site(bp): 50009005 End Site(bp): 50009026 External Links: hsa-miR-362-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand PTPRJ chr11 47980558 48170841 + KIAA0232 chr4 6781375 6884170 + USF2 chr19 35268962 35279821 + BLCAP chr20 37492472 37527931 - AC009133.6 chr16 29812261 29820092 + WDR82 chr3 52254434 52288020 - PIP4K2B chr17 38765689 38800126 - ARF3 chr12 48935723 48957487 - TRPS1 chr8 115408496 115809673 - UBTF chr17 44205033 44221626 - FAM126B chr2 200973718 201071671 - ZBTB2 chr6 151364115 151391559 - TNFRSF21 chr6 47231532 47309905 - RUNX1 chr21 34787801 36004667 - MTPN chr7 135926760 135977359 - SERTAD3 chr19 40440844 40444335 - DCBLD2 chr3 98795941 98901695 - ATP8B1 chr18 57646426 57803315 - SLF2 chr10 100912963 100965134 + SDCBP chr8 58552924 58582859 + TNFRSF1B chr1 12166991 12209228 + COQ8A chr1 226897536 226987545 + DNAJB9 chr7 108569867 108574850 + VAMP2 chr17 8159149 8163546 - SIK1B chr21 6111131 6123778 + SMAP2 chr1 40344850 40423326 + FAM219A chr9 34398184 34458570 - CA12 chr15 63321378 63381846 - CALM1 chr14 90396502 90408268 + AKAP11 chr13 42272152 42323261 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001588 chr6 26204839 26205043 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - KCNQ1OT1 chr11 2608328 2699994 - MIR663AHG chr20 26167817 26251546 - NEAT1 chr11 65422774 65445540 + SCARNA9 chr11 93721513 93721865 + SNHG25 chr17 64145970 64146476 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.